Vir Biotechnology/$VIR
1D1W1MYTD1Y5YMAX
Capital at risk
About Vir Biotechnology
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
- Ticker
- $VIR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 367
- Headquarters
- San Francisco, United States
- Website
- www.vir.bio
VIR Metrics
BasicAdvanced
$1.8B
-
-$1.70
1.59
-
Price and volume
Market cap
$1.8B
Beta
1.59
52-week high
$11.94
52-week low
$4.82
Average daily volume
2.1M
Financial strength
Current ratio
6.042
Quick ratio
5.669
Long term debt to equity
0.086
Total debt to equity
0.095
Profitability
EBITDA (TTM)
-267.958
Gross margin (TTM)
-59.39%
Net profit margin (TTM)
-83.00%
Operating margin (TTM)
-92.16%
Effective tax rate (TTM)
-0.15%
Revenue per employee (TTM)
$830,000
Management effectiveness
Return on assets (TTM)
-14.51%
Return on equity (TTM)
-26.08%
Valuation
Price to revenue (TTM)
5.215
Price to book
1.84
Price to tangible book (TTM)
1.88
Price to free cash flow (TTM)
-7.767
Free cash flow yield (TTM)
-12.87%
Free cash flow per share (TTM)
-1.372
Growth
Revenue change (TTM)
1,495.93%
Earnings per share change (TTM)
-57.61%
3-year revenue growth (CAGR)
-14.83%
3-year earnings per share growth (CAGR)
-4.74%
What the Analysts think about VIR
Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.
Analyst projections of the future price of Vir Biotechnology stock.
Bulls say / Bears say
The Phase 2 SOLSTICE study produced strong long-term HDV data: 88% of patients on elebsiran plus tobevibart had undetectable HDV RNA at Week 96, with no treatment-related serious adverse events or discontinuations reported. That supports the combination’s potential to become an effective and tolerable treatment. (Financial Times)
Vir has fully enrolled its ECLIPSE registrational programme, with Phase 3 ECLIPSE 1 data expected in the fourth quarter of 2026 and further readouts due in the first quarter of 2027. These are clear, near-term catalysts that could move the HDV programme towards regulatory filings. (Financial Times)
The Astellas collaboration gives Vir a major industry partner for VIR-5500 and strengthened its balance sheet with a $240 million upfront payment and a $75 million equity investment. Vir reported about $1.01 billion in cash, cash equivalents and investments at the end of June and expects funding into the second half of 2028. (Financial Times)
Vir faces established and emerging competition in HDV. Gilead’s Hepcludex became the first FDA-approved HDV treatment in May, while Mirum reported positive Phase 2b data for brelovitug and is advancing it through Phase 3 trials. (Reuters, Financial Times)
Vir’s second-quarter net income was largely driven by $238.9 million of licence and collaboration revenue from the Astellas upfront payment, rather than recurring product sales. As a clinical-stage company, it remains dependent on future trial success and additional partnerships or financing to create sustainable revenue. (Financial Times)
The oncology portfolio is still early and unproven: VIR-5500 is in Phase 1 dose expansion, VIR-5818 remains in Phase 1, and pivotal VIR-5500 trials are only anticipated to begin in 2027. This leaves substantial safety, efficacy and execution risk before these programmes can generate value. (Financial Times)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.
VIR Financial Performance
Revenues and expenses
VIR Earnings Performance
Company profitability
Upcoming events
No upcoming events
VIR News
AllArticlesVideos
Funds containing VIR
AllUSDEURGBP
Fund name | Fund size | $VIR weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.15% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.15% |
iShares Healthcare Innovation£DRDR | £1B | 0.15% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.12% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.